MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, has filed its 2014 Registration Document (Document de Référence) with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on September 2, 2015 under the number R. 15-064.
The 2014 Registration Document includes:
- the consolidated financial statements as of December 31, 2014 and the related statutory auditors' report,
- the information on the fees received by the auditors, and
- the required information in relation to the Company’s share buyback program.
The Registration Document is available free of charge at THERACLION, 102, rue Etienne Dolet – 92240 Malakoff and may be viewed or downloaded on the Theraclion’s website (www.theraclion.com) and on the AMF's website (www.amf-france.org).
About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic:
ALTHE - ISIN Code: FR0010120402